Welcome to our dedicated page for Bowen Acquisition SEC filings (Ticker: BOWNR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Bowen Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Bowen Acquisition's regulatory disclosures and financial reporting.
Bowen Acquisition Corp held an extraordinary general meeting where shareholders approved an amendment allowing the board to extend the deadline to complete an initial business combination. The change was adopted by special resolution under the company’s amended and restated memorandum and articles of association.
A quorum of 2,727,780 ordinary shares was represented at the meeting. The proposal passed with 2,723,387 votes for, 4,376 against and 17 abstentions. Bowen Acquisition Corp states it is continuing to attempt to satisfy the remaining conditions to close its proposed business combination with Shenzhen Qianzhi BioTechnology Co. Ltd.
Bowen Acquisition Corp is asking shareholders to approve an extension of its SPAC deadline to complete a business combination from June 14, 2026 to as late as December 31, 2026, and to approve a possible adjournment of the meeting if more time is needed.
The SPAC has a pending, already‑approved merger with Shenzhen Qianzhi BioTechnology but has not yet closed it. Public shareholders can elect to redeem their shares for cash from the trust account, estimated at about $11.55 per share based on approximately $7.78 million held in trust as of May 22, 2026, if they submit redemption requests by June 9, 2026.
If the extension is not approved and no deal is completed by June 14, 2026, Bowen would wind up, redeem all public shares from the trust and liquidate, while founder and private shares would receive no trust proceeds. Sponsors and insiders hold about 70.3% of outstanding shares and intend to vote in favor of the extension, effectively assuring its approval if all shares vote. The proxy also highlights risks including prior Nasdaq delisting, limited trading liquidity, potential Investment Company Act issues, CFIUS-related constraints because of foreign ties, and conflicts of interest for sponsors and management.
Bowen Acquisition Corp. filed a Form 12b-25 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company says additional time is needed to compile and process required information because it lacks full-time accounting and administrative staff and is pursuing an initial business combination. The notification was signed by Jiangang Luo, CEO, on May 15, 2026.
Bowen Acquisition Corp (BOWN) is calling an extraordinary general meeting on December 12, 2025 for shareholders to vote on extending the deadline to complete its initial business combination. The Extension Proposal would allow the board to push the current termination date from December 14, 2025 by up to six one‑month increments, to as late as June 14, 2026. A separate Adjournment Proposal would let the board adjourn the meeting if more time is needed to secure approval.
Bowen has a signed deal with Shenzhen Qianzhi BioTechnology Co. Ltd., which shareholders approved in January 2025 but has not yet closed. Public shareholders may elect to redeem their shares for cash; based on about $8.26 million in the trust as of November 20, 2025, the company estimates a redemption price of roughly $11.35 per share. If the Extension Proposal fails and no deal closes by December 14, 2025, Bowen would redeem all public shares and liquidate. Shareholders who do not redeem now, and did not redeem at the earlier Qianzhi vote, will not have redemption rights when that business combination is completed.